poisar

Stocks · News reference

Guggenheim Maintains Veracyte Buy Rating, Cuts Target Price to $35

Fiscal.ai

Guggenheim analyst Subbu Nambi has maintained a 'Buy' rating on Veracyte, Inc. while lowering the price target to $35.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading